SABS · NASDAQ · Biotechnology

SAB Biotherapeutics (SABS)

Develops a fully human polyclonal-antibody therapy for newly diagnosed autoimmune diabetes.

$3.60
Pre-market−0.15 (−4.00%)
At close$3.75(+1.35%)

Something off on this page? Send us feedback.

Next report
Nov 13, 2026
estimated · in 71 days
EPS estimate
−$0.27
Revenue estimate
$125.0K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$1.23−$0.56−$1.09−$0.21−$0.46−$0.35−$0.28Pending
Estimate−$1.16−$1.00−$0.82−$0.59−$0.16−$0.20−$0.28−$0.27
Surprise−6.0%+44.0%−32.9%+64.4%−187.5%−75.0%+1.1%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$100.0KPending
Estimate$120.0K$125.0K$83.3K$100.0K$100.0K$125.0K$125.0K$125.0K
Surprise−16.7%

History

DateEstimateReportedSurprise
Nov 2026−$0.27
Aug 2026−$0.28−$0.28+1.1%
May 2026−$0.20−$0.35−75.0%
Mar 2026−$0.16−$0.46−187.5%
Nov 2025−$0.59−$0.21+64.4%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Aug 2023
May 2023
Apr 2023
Nov 2022
Aug 2022
May 2022
Mar 2022
Nov 2021
Aug 2021
May 2021
Apr 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 13, 2026−$0.27$125.0K
Aug 6, 2026−$0.28−$0.28+1.1%$125.0K+2.1%
May 12, 2026−$0.20−$0.35−75.0%$125.0K+9.4%
Mar 9, 2026−$0.16−$0.46−187.5%$100.0K+6.8%
Nov 14, 2025−$0.59−$0.21+64.4%$100.0K+8.0%

The latest year is open to everyone — the 19 quarters behind it read with an account.

Sign in
Aug 7, 2025
May 9, 2025
Mar 28, 2025
Nov 6, 2024
Aug 8, 2024
May 20, 2024
Apr 1, 2024
Nov 13, 2023
Aug 21, 2023
May 16, 2023
Apr 14, 2023
Nov 15, 2022
Aug 10, 2022
May 12, 2022
Mar 29, 2022
Nov 22, 2021
Aug 9, 2021
May 21, 2021
Apr 2, 2021